NCT07277322 2026-03-02
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Icahn School of Medicine at Mount Sinai
Phase 1/2 Not yet recruiting
Clinical Trials
7 trialsNCT05013450 2025-12-17
Dupilumab_Metastatic NSCLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Active not recruiting
NCT06637306 2025-03-26
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Recruiting
NCT06743581 2024-12-20
Dupi-Cemi
Centre hospitalier de l'Université de Montréal (CHUM)
Phase NA Not yet recruiting
NCT05967884 2023-08-01
PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer
Ottawa Hospital Research Institute
Phase 2 Unknown
NCT03736967 2021-11-01
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT03886493 2021-10-15
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated